HCV Treatment
Antiviral Activity of Interferon beta-1a with or without Ribavirin in Asian Patients with Chronic Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 28 August 2007 14:03
- Written by HIVandHepatitis.com
Treatment with pegylated interferon alpha-2a (Pegasys) or pegylated interferon alpha -2b (PegIntron) plus ribavirin is the current standard of care for treatment of chronic hepatitis C virus (HCV) infection. This regimen produces a sustained virological response (SVR) in approximately 50%-60% of patients.
Asian Patients Appear to Respond Better than Whites to Pegylated Interferon Plus Ribavirin for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 14 August 2007 14:03
- Written by Liz Highleyman
As reported in the July 19, 2007 advance online edition of the American Journal of Gastroenterology, researchers with the Canadian Pegasys Expanded Access Group conducted a study to determine whether Asian race/ethnicity is an independent predictor of response to antiviral therapy in patients with hepatitis C.
Anadys to Halt Development of Investigational Hepatitis C Drug ANA975
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 03 August 2007 14:03
- Written by Anadys
Anadys Pharmaceuticals announced last week that it will discontinue development of its investigational anti-HCV drug candidate, ANA975, a toll-like receptor 7 agonist.Anadys was developing the agent in collaboration with Novartis. The decision comes in the wake of disappointing data from toxicology studies in animals. Toll-like receptor agents can cause excessive immune stimulation, leading to a range of side effects.
Web Design and Development by